Catalyst Event
InnoCare Pharma Ltd (9969) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
4/28/2026, 12:00:00 AM
On 2026-04-28, InnoCare announced the first patient has been dosed in its Phase III registrational clinical trial for Orelabrutinib for the treatment of systemic lupus erythematosus (SLE). This clinical milestone is estimated to have a ~5% price impact as it advances a key pipeline asset.
Korean Translation
2026년 4월 28일, 전신성 홍반성 루푸스(SLE) 치료를 위한 오레라브루티닙(Orelabrutinib)의 3상 등록 임상시험에서 첫 환자 투여를 완료했다고 발표함. 주요 파이프라인의 임상 진전에 따라 약 5%의 주가 영향이 예상됨.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
Extraordinary shareholders' meeting to appoint a former Financial Supervisory Service (FSS) official as a new outside director on June 30, 2026. Low importance is estimated as board changes typically have minimal immediate price impact, scheduled.
6/30/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.
5/18/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Earnings Release
Q1 2026 earnings release on May 18, 2026. Low importance is estimated as the announcement of the release date itself usually results in minimal price movement, scheduled.
5/18/2026, 12:00:00 AM
Celltrion Inc (068270) · Earnings Release
Celltrion is scheduled to announce its Q1 2026 earnings on May 8, 2026. Analysts forecast consolidated sales of approximately 1.12 trillion KRW and an operating profit of around 314 billion KRW, which is estimated to have a medium market impact (≥5%) scheduled.
5/8/2026, 12:00:00 AM
Samsung Biologics Co Ltd (207940) · Other
The company's labor union has threatened its first-ever general strike to begin on May 1, 2026, following the breakdown of wage negotiations. Analysts forecast a price impact of over 10% due to significant operational risks, expected.
5/1/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Celltrion applied for marketing authorization to the European Medicines Agency (EMA) for 'Herzuma SC', a subcutaneous formulation of its breast cancer biosimilar Trastuzumab, on April 30, 2026. This first-in-class formulation is estimated to have a high market impact (≥10%) due to its significant competitive advantage.
4/30/2026, 12:00:00 AM